Daniela E Aust
Overview
Explore the profile of Daniela E Aust including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong F, Merker S, Bauer L, Han Y, Le V, Wenzel C, et al.
Br J Cancer
. 2025 Jan;
132(4):326-339.
PMID: 39863771
Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits a high frequency of neural invasion (NI). Schwann cells (SCs) have been shown to be reprogrammed to facilitate cancer cell migration and invasion into...
2.
Saalfeld F, Moller J, Christopoulos P, Wenzel C, Rasokat A, Wang X, et al.
Eur J Cancer
. 2024 Oct;
213:115065.
PMID: 39423775
Introduction: Small cell transformation (SCT) is a typical mechanism of adaptive resistance to third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the standard of care for EGFR-driven...
3.
Kerle I, Scheuble A, Kobitzsch B, Stocker G, Hiller G, Badendick M, et al.
JCO Precis Oncol
. 2024 May;
8:e2400030.
PMID: 38820503
Complete remission of BRAF V600E-driven ACC CUP by BRAF/MEK inhibition underscores importance of precision oncology.
4.
Illini O, Saalfeld F, Christopoulos P, Duruisseaux M, Vikstrom A, Peled N, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612799
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed...
5.
Saalfeld F, Aust D, Wermke M
Dtsch Med Wochenschr
. 2023 Sep;
148(18):1166-1173.
PMID: 37657454
In no other cancer is clinical practice as close to the ideals of personalized oncology as in the treatment of non-small cell lung cancer (NSCLC). Here, we briefly outline the...
6.
Aust D, Baretton G, Sommer U
Pathologie (Heidelb)
. 2023 Jun;
44(5):294-300.
PMID: 37311872
Ulcerative colitis (UC) is a chronic inflammatory bowel disease beginning in the rectum and gradually extending to the right-sided colon and the terminal ileum (backwash-ileitis). Its causes are still not...
7.
Heiduk M, Klimova A, Reiche C, Digomann D, Beer C, Aust D, et al.
Clin Cancer Res
. 2023 May;
29(14):2638-2650.
PMID: 37140899
Purpose: Immunotherapy has led to a fundamental shift in the treatment of several cancers. However, its efficacy in pancreatic ductal adenocarcinoma (PDAC) is limited. Understanding the expression of inhibitory immune...
8.
Westphal D, Meinhardt M, Grutzmann K, Schone L, Steininger J, Neuhaus L, et al.
J Invest Dermatol
. 2023 Jan;
143(7):1233-1245.e17.
PMID: 36716920
Despite remarkable advances in treating patients with metastatic melanoma, the management of melanoma brain metastases remains challenging. Recent evidence suggests that epigenetic reprogramming is an important mechanism for the adaptation...
9.
Heiduk M, Plesca I, Gluck J, Muller L, Digomann D, Reiche C, et al.
JCI Insight
. 2022 Dec;
7(22).
PMID: 36509285
BACKGROUNDPancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%-40% of...
10.
Peuker K, Strigli A, Tauriello D, Hendricks A, von Schonfels W, Burmeister G, et al.
Immunity
. 2022 Apr;
55(4):701-717.e7.
PMID: 35364006
Bacterial sensing by intestinal tumor cells contributes to tumor growth through cell-intrinsic activation of the calcineurin-NFAT axis, but the role of this pathway in other intestinal cells remains unclear. Here,...